The NHS England announces it will reimburse Novartis CAR-T cell therapy Kymriah as treatment for children with B cell acute lymphoblastic leukemia (ALL) that are refractory, in relapse post-transplant or in second or later relapse.
Exosome drug delivery specialist Evox Therapeutics Ltd has closed a 37.1m (£35.5m) Series B financing round led by Redmile Group and significant contributions from GV (Google Ventures) and Cowen Healthcare Investments.
The EU approved Sanofis Cablivi (caplacizumab) as the first antibody therapeutic to treat acquired thrombotic thrombocytopenic purpura (aTTP) on Friday.
An FDA-approved cancer drug stops light sensitivity of the skin in Cockayne syndrome (CS), an ultra-rare hereditary disease characterised by premature aging, German researchers report.
Germanys government announced that it will create an agency for breakthrough ("jump") innovation to foster technology transfer of risky research projects with high market potential into products.
Urovant Sciences has licensed the global commercialisation rights for Ion Channel Innovations gene therapy hMaxi-K for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy.
Roches US arm Genentech has licenced Affimed NVs ROCK platform to add multivalent antibodies, which could activate the innate immune system, to its cancer pipeline.
The British Heart Foundation (BHF) will tender £30m (33.2m) to tackle the suffering and devastation caused by heart and circulatory diseases.
Orphan drug leader Shire plc (Dublin), has received the FDAs approval for its antibody lanadelumab-flyo, which prevents hereditary angioedema (HAE) attacks.
Blocking the extracellular matrix (ECM) enzyme leukotriene A4 hydrolase (LTA4H) dampens inflammation but promotes changes in the airways of mice with allergic asthma due to accumulation of the ECM degradation product PGP.